bpc 157 human clinical trials musculoskeletal BPC-157 and the Difference Between an Evidence Gap and a Cover-Up: What the entire evidence base actually looks like, and the questions to ask next. — WellFounded BPC-157 vs. TB-500: What Patients

For glycemic control in type 2 diabetes, treatment is typically continued indefinitely as long as it remains effective and well-tolerated, with periodic assessment of the ongoing need for therapy

Examples include: peptide therapy (at high doses or long-term use) TB-500 (Thymosin Beta-4) VEGF-mimetic peptides Tesamorelin/peptide therapy (via IGF-1 pathways) Potential risks of prolonged use: Scar tissue overdevelopment Feeding abnormal or cancerous cell growth Disrupting blood flow in sensitive tissues (eyes, kidneys) Thats why we recommend cycles like: TB-500 : 610 weeks on, 4+ weeks off peptide therapy injections : short-term, with oral BPC for maintenance Tesamorelin/peptide therapy : rotated or paused to avoid overexposure Other Peptides That Benefit From Cycling Even non-angiogenic peptides benefit from breaks: Thymosin Alpha-1 : 5-week cycles, 23x per year GHK-Cu : 78 week cycles, followed by rest Semax & Dihexa : pulsed use to maintain brain sensitivity 5-Amino-1MQ : cycled after 23 rounds for metabolic reset Each protocol is tailored to half-life, tissue targets, and sensitivity feedback

Shaking instead of swirling

And then in my postdoc, I did my postdoc with Dr

2018;45(Suppl 20):S16270

For 10 mg/mL, add 1.0 mL